Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.
Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy
JR Rahn is stepping down as MindMed's CEO, to be replaced by Chief Development Officer, Robert Barrow.
Mydecine announces identifying 40 previously unknown "novel compounds" among dozens of mushroom species it has screened.
Cybin is launching a new clinical trial to address "COVID-related burnout and distress", supported by its new EMBARK psychotherapy model.
Red Light Holland's new tech acquisition is intended to help optimize psychedelics dosing.
Optimi Health's new distribution agreement with Vitasave provides retail access to two of Canada's largest urban markets.
After just uplisting to the TSX in Canada, Field Trip Health has applied to uplist to the NASDAQ in the U.S.
Field Trip Health has uplisted to the TSX in Canada.
A Psychedelic Drug Revolution is underway to address the Mental Health Crisis. As with all revolutions, we are seeing a rapid shift in attitudes.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now